Unlock the potential of biosimilars: Improve patient access and long-term healthcare sustainability

Memo

Since the world’s first biosimilar was approved in 2006, these treatments have had a positive impact on patient access and healthcare system sustainability. However, despite 15 years of progress, several challenges need to be addressed in order to unlock their full potential. With mounting pressures testing current healthcare models to their limits, it has never been more important to take action to deliver long-term sustainability while ensuring patient access to medicines. Could biosimilars hold the key? Join us for this exclusive panel event featuring insights and interviews with experts from patient groups, healthcare (pharmacist), data science, and the pharmaceutical industry as we discuss evolving barriers to biosimilars adoption worldwide and work toward solutions to improve access and affordability across the globe. Speakers: Murray Aitken, Executive Director, IQVIA Institute for Human Data Science, Antonella Cardone, Director, European Cancer Patient Coalition, Pierre Bourdage, Global Head Biopharmaceuticals, Sandoz, Rebecca Guntern, Head of Region Europe, Sandoz , Robert Spina, VP, Marketing, Market Access & Patient Services, Sandoz, Prof. Dr. Arnold G. Vulto, Hospital Pharmacist n.p. Educator and consultant on Biopharmaceuticals / Biosimilars, VuPEC Time: 3:00 pm - 5:00 pm